DA32 Life Science Tech Acquisition Corp. (DALS)
DA32 Life Science Tech Acquisition Corp. is a blank check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
In coming together as co-sponsors of DA32, Deerfield Management, ARCH Venture Partners and Section 32 aim to leverage their complementary capabilities and networks in order to acquire, merge with and grow a promising life science technology opportunity.
We intend to focus our search for business combination targets in four separate areas of the larger life sciences industry, including: Life Sciences Tools, Diagnostics, Synthetic Biology, and Data and Analytics Platforms.
|IPO Date||Jul 28, 2021|
345 Park Avenue South, 12th Floor
New York, NY 10010
|Reporting Currency||US Dollars|
|Dr. Steven Kafka Ph.D.||Chief Executive Officer and Director|
|Christopher E. Wolfe||Chief Financial Officer and Secretary|